Top High Growth Tech Stocks To Watch In September 2024

Over the last 7 days, the market has dropped 2.7%. As for the longer term, the market has risen by 21% in the last year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks that can capitalize on these trends becomes crucial for investors looking to maximize their returns.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
TG Therapeutics	28.39%	43.54%	★★★★★★
Sarepta Therapeutics	24.22%	44.94%	★★★★★★
Super Micro Computer	20.62%	27.13%	★★★★★★
Ardelyx	27.44%	65.50%	★★★★★★
G1 Therapeutics	27.57%	57.75%	★★★★★★
Invivyd	42.91%	70.39%	★★★★★★
Ascendis Pharma	39.71%	68.43%	★★★★★★
Clene	73.06%	62.58%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 251 stocks from our US High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Aurinia Pharmaceuticals (NasdaqGM:AUPH)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for diseases with unmet medical needs in the United States, with a market cap of approximately $998.08 million.

Operations: Aurinia Pharmaceuticals generates revenue primarily through the research, development, and commercialization of therapeutic drugs, amounting to $207.11 million. The company operates within the United States market.

Aurinia Pharmaceuticals is making significant strides in the tech-driven biotech sector, with its R&D expenses reflecting a strong commitment to innovation. The company’s revenue is forecasted to grow at 17.6% annually, outpacing the US market's 8.6%. Earnings are projected to increase by an impressive 54.61% per year, highlighting robust growth prospects. Recently, Aurinia's AUR200 entered Phase 1a trials, targeting autoimmune diseases with a unique dual inhibition mechanism of BAFF and APRIL—showcasing potential for high-impact therapeutic advancements.

• Click here to discover the nuances of Aurinia Pharmaceuticals with our detailed analytical health report.

• Learn about Aurinia Pharmaceuticals' historical performance.

CI&T (NYSE:CINT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: CI&T Inc. (NYSE:CINT) offers strategy, design, and software engineering services to facilitate digital transformation for businesses globally and has a market cap of $905.98 million.

Operations: The company generates revenue primarily from its computer services segment, which contributed R$2.14 billion. Gross profit margin stands at 35%.

CI&T's earnings are projected to grow at an impressive 33% annually, outpacing the US market's 14.9%. Despite a slight revenue dip in the first half of 2024, their R&D investments have been substantial, contributing to innovative solutions and client acquisitions. The company's recent share buyback of over 1.3 million shares for BRL 26.88 million indicates confidence in its future prospects. Software firms' shift to SaaS models could bolster CI&T’s recurring revenue streams significantly.

• Get an in-depth perspective on CI&T's performance by reading our health report here.

• Assess CI&T's past performance with our detailed historical performance reports.

Envestnet (NYSE:ENV)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Envestnet, Inc. provides wealth management software and services both in the United States and internationally, with a market cap of approximately $3.47 billion.

Operations: Envestnet generates revenue primarily from its two segments: Envestnet Data & Analytics ($147.55 million) and Envestnet Wealth Solutions ($1.16 billion). The company's offerings include a suite of software and services designed to support wealth management professionals both domestically and internationally.

Envestnet's revenue growth is forecasted at 8.9% annually, surpassing the US market's 8.6%, with earnings expected to rise by an impressive 72.78% per year over the next three years. Despite a net loss of $79.2 million in Q2 2024, compared to $21.42 million a year ago, their R&D expenses reflect significant investment in innovation and client acquisition strategies, contributing to future profitability prospects. The recent acquisition deal valued at $3.6 billion underscores investor confidence in Envestnet’s potential amidst its evolving business landscape.

• Take a closer look at Envestnet's potential here in our health report.

• Understand Envestnet's track record by examining our Past report.

Make It Happen

• Embark on your investment journey to our 251 US High Growth Tech and AI Stocks selection here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com